For type 2 diabetes, the focus may include A1C, cardiovascular history, kidney status, hypoglycemia risk, and current medicines
What to Tell Patients About Peptides When patients ask Mendias about peptides, he focuses on safety data and treats it like an illicit drug use conversation, eventually moving to a gentle follow-the-money discussion
Lets break this down clearly
But it also leads me to wanting to say its interesting, because if that had been our motivation to actually say, oh, there's weight loss in diabetes, let's pursue it in people with obesity, I don't think we would've done that because the weight loss in people with diabetes wasn't that impressive
It doesnt force anything unnatural